The EMA will publish a conclusion on the risks of thrombosis in J&J vaccinated patients

The European Medicines Agency (EMA) will hold a briefing on Tuesday, April 20, to report on the risk assessment results of thromboembolic complications in those vaccinated with the Johnson & Johnson coronavirus vaccine, the regulator said in a statement.

It is reported that the briefing will be attended by the Executive Director of the EMA, Emer Cooke as well as the head of the pharmacovigilance committee, Sabine Strauss.

Formerly the Food and Drug Administration (FDA) the US and the Centers for Disease Control and Prevention (CDC) have recommended suspending vaccination against COVID-19 with Johnson & Johnson’s Janssen pharmacology unit “as a precautionary measure.”

The American company Johnson & Johnson issued a press release in which it announced that it had decided to postpone the use of its coronavirus vaccine in Europe. The company said that it is aware of cases of blood clots after vaccination with J&J.

The EMA, in turn, said it would conduct a risk assessment of the vaccine and publish its scientific opinion.

Author: Steve Cowan
Graduated From Princeton University. He has been at the Free Press since October 2014. Previously worked as a regional entertainment editor.
Function: Chief-Editor
133 number 0.232340 time